![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, February 07, 2024 10:18:01 AM
February 01, 2024
Vivos Inc. Q4 2023 Update | IsoPet® - RadioGel™
Quarterly Progress Report – Q4 2023
Animal Business Sector
Marketing
Vivos Inc participated in seven conferences in 2023. This quarter we had booths in the Veterinary
Cancer Society, the American Association of Equine Practitioners, and the Wild West Vet Show.
Potential New Equine Market
Dr. Bill Bradly, owner of the New England Equine Practice, conducted an experiment to determine if
IsoPet is effective in treating caudal heel pain syndrome, sometimes called navicular syndrome. The
control test showed promise. In Q1, 2024 he will conduct a therapy on an equine patient that is in
pain. If IsoPet is effective this is a potential new and large market.
Medical Business Sector
Breakthrough Designation
The Food and Drug Administration has granted RadioGelTM Precision Radionuclide TherapyTM the
designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program. Our Risk
Management Report and supporting data concludes that RadioGel™ is intrinsically safe and our animal
therapy data verifies its effectiveness. The FDA’s Breakthrough Devices program will enhance the
schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.
Submittal of the IDE - (Q211938/S001)
The key ongoing activities for next IDE application are summarized below:
Mayo Clinic Protocol
We refined the Mayo Clinical Trial Protocol by integrating the previous comments from the FDA, the
comments from the gatekeeper to the Mayo Clinic Institutional Review Board, and from the lessons
learned from the Johns Hopkins VX2 Animal Study, which treated tumors in the same size range.
Next quarter we are planning to complete the final training certification steps for human therapy.
VX-2/Rabbit Animal Study
We completed the testing phase of the study and are now writing the report.
Genotoxicity
We participated in the Pre-Sub meeting with the FDA to gain a consensus on the Genotoxicity
Chemical Characterization Protocol. We have now completed the first phase of the testing.
Quality Management System
Before initiating human clinical trials, the FDA usually conducts a thorough audit of the quality
management system at the production site. Over the last three years we have strengthened our
Quality Management System. This quarter we conducted the required annual Design Review
Meeting to incorporate the 2023 improvements and created or amended 15 additional documents.
Intellectual Property
Intellectual property protection is always a priority and will become increasingly important, for
example, if we pursue international licensing our team with a major medical corporation.
This quarter we filed a utility patent for our Peltier Chiller and the support equipment. This proprietary.
equipment is being used by our regional animal therapy clinics and, in the future, by hospitals for
human therapy.
We previously patented our particles and our hydrogel, as well as potentiall new particles that
administer gamma and alpha radiation. We also have trademark protection for (IsoPet®, RadioGelTM
and Precision Radionuclide TherapyTM.
Recent RDGL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 05:58:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 05:56:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 05:26:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 01:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 05:16:12 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 07/17/2024 04:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 07/15/2024 10:02:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 06:28:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:40:48 PM
- Form 1-A POS - • Edgar (US Regulatory) • 11/27/2023 10:29:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 04:28:46 PM
- Form 1-A POS - • Edgar (US Regulatory) • 11/03/2023 09:03:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 04:18:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 10:33:58 AM
- Form 1-A POS - • Edgar (US Regulatory) • 10/10/2023 04:05:36 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM